About RNA-binding protein 42
RNA-binding protein 42 (RBM42) is a protein
from Homo sapiens identified by UniProt accession
Q9BTD8, 480 residues long.
MolForge cross-references it against 0 known binders and
14 disease associations.
Target properties
| Protein name | RNA-binding protein 42 |
| UniProt accession | Q9BTD8 |
| Gene | RBM42 |
| Organism | Homo sapiens |
| Length | 480 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (14)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.54
- lysosomal storage disease · score 0.31
- neoplasm · score 0.01
- punctate palmoplantar keratoderma type III · score 0.01
- hepatitis B virus infection · score 0.01
- immature platelet fraction · score 0.01
- chronic obstructive pulmonary disease · score 0.01
- astrocytoma · score 0.00
- Thrombocytopenia · score 0.00
- Au-Kline syndrome · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BTD8-F1 | alphafold | PREDICTED | 62.03 | — |
Amino-acid sequence (480 residues)
MAGAGPAPGL PGAGGPVVPG PGAGIPGKSG EERLKEMEAE MALFEQEVLG APVPGIPTAV PAVPTVPTVP TVEAMQVPAA PVIRPIIATN TYQQVQQTLE ARAAAAATVV PPMVGGPPFV GPVGFGPGDR SHLDSPEARE AMFLRRAAVA PQRAPILRPA FVPHVLQRAD SALSSAAAGP RPMALRPPHQ ALVGPPLPGP PGPPMMLPPM ARAPGPPLGS MAALRPPLEE PAAPRELGLG LGLGLKEKEE AVVAAAAGLE EASAAVAVGA GGAPAGPAVI GPSLPLALAM PLPEPEPLPL PLEVVRGLLP PLRIPELLSL RPRPRPPRPE PPPGLMALEV PEPLGEDKKK GKPEKLKRCI RTAAGSSWED PSLLEWDADD FRIFCGDLGN EVNDDILARA FSRFPSFLKA KVIRDKRTGK TKGYGFVSFK DPSDYVRAMR EMNGKYVGSR PIKLRKSMWK DRNLDVVRKK QKEKKKLGLR
Explore RNA-binding protein 42 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets